Sorafenib in Advanced Hepatocellular Carcinoma
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates prolonged survival with sorafenib in advanced hepatocellular carcinoma, highlighting a new systemic treatment option.
Key Points
- To evaluate the efficacy and survival impact of sorafenib compared with placebo in patients with advanced hepatocellular carcinoma.
- Randomized, placebo-controlled clinical trial evaluating oral sorafenib in patients diagnosed with advanced hepatocellular carcinoma (ClinicalTrials.gov number, NCT00105443).
- Evaluated primary clinical endpoints including median overall survival and time to radiologic tumor progression.
- Median overall survival was prolonged by nearly 3 months for patients receiving sorafenib compared to those given placebo.
- Time to radiologic progression was extended by nearly 3 months in the sorafenib group relative to the placebo arm.
Cite This Study
Llovet et al. (2008) studied this question.